Kornimate/medical-research-clean huggingface dataset:
translating 3-step workout for life in a local senior living community

Conditions: Frail Elderly; Muscle Weakness

Summary: the study evaluates the feasibility of a staff-lead workout program, 3-step workout for life, in a local senior living community. eligible participants will complete assessments before and after the workout program.

the 3-step workout for life program is designed to help older adults improve muscle strength and apply the improved muscle strength to perform activities of daily living. the 10-week workout consists of single-joint resistance exercise, multiple-joint resistance exercise, and activities of daily living exercise. participants will exercise in small groups in a community room as well as one-on-one with the fitness staff in their home. the community fitness staff will learn the 3-step workout for life program from the university partner and deliver the program.

Eligibility criteria:
inclusion criteria: 1. aged 60 years old and above 2. residents of the local study community 3. communicable in english 4. took more than 16 seconds to complete five chair stands with arms crossed at the chest. 5. self-reported difficulty in performing one or more activities of daily living, which must include difficulty in feeding/eating, dressing, grooming/personal hygiene, bathing/showering, using the toilet, or functional mobility/transfer. exclusion criteria: 1. aged above 90 years old. 2. unwilling to commit to the study program 3 sessions per week for 10 weeks. 3. plan to move away from the current community in 6 months. 4. having three or more errors on a six-item cognitive impairment screener. 5. having any terminal illness, cardiovascular, neurological, psychiatric, orthopedic, or cognitive impairments that are contraindications to participating in an exercise program. 6. the difficulty of performing activities of daily living is due to neurological disorders (e.g., stroke, parkinson's), orthopedic conditions (e.g, amputees), or sensory deficits (diabetic palsy, low vision). 7. physician's recommendation of no moderate physical exercise. 8. receiving home health rehabilitation therapy or exercise at moderate intensity for more than twice a week (last more than 20 minutes each time).

Keywords: occupational therapy aging in place activities of daily living community program
concussion in french amateur rugby : survey about the management and knowledge of players

Conditions: Cerebral Concussion

Summary: rugby is a popular contact sport in france the majority of whom are amateur players. concussion is one of the main risks given its potential severity and frequency (between 2.78 and 10 per 1,000 player hours). faced with a concussion, stop sport activity, medical evaluation and a progressive resumption of activity are simple things to do to avoid an over-risk of injury and better recovery of the player. for this purpose, the rugby federation implement the blue card and the concussion declaration by clubs. a recent study showed that the directives of the federation are not sufficiently respected. the non-declaration problem is added knowing that around 50% of concussions are not declared. in professional rugby, the presence of a medical staff makes possible to optimize care as much as possible. in the amateur world, there are not always medical or paramedical personnel trained for this problem at the edge of the field when all the participants (player, coach, coaching) lack of knowledge on the subject and that the general practicer remains the referent for the concussion management. we will reach a dozen amateur rugby club to complete a questionnaire about concussions and conduct un formation session about this issue.


Eligibility criteria:
inclusion criteria: * male 18 years of age or older * amateur rugby players in a club of new aquitaine region who agreed to participate * licensed with the federation for 2019/2020 or 2020/2021 season * between the federal 1 and the 4th series exclusion criteria: - refusal to complete the questionnaire

Keywords: cerebral concussion systems thinking injury management sport-related injury rugby union mild traumatic brain injury
safety and effectiveness of giving an anti-hiv drug combination of adefovir dipivoxil plus didanosine plus efavirenz plus lamivudine once daily to hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give hiv-infected patients a new combination of anti-hiv drugs taken once daily.

patients receive a treatment regimen of adefovir dipivoxil, didanosine, efavirenz, and lamivudine for 48 weeks. during the study, patients are evaluated for changes from baseline in plasma hiv-1 rna and lymphocyte subsets and for the development of adverse experiences and laboratory toxicities. at weeks 8, 12, 24, and 48, patients are assessed for adherence to study treatment with a questionnaire. patients who experience virologic failure are discontinued from the study. patients who experience treatment intolerance may have their antiretroviral treatment regimens changed. after week 48, patients with documented virologic response are eligible to continue receiving study treatment.

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are hiv-positive. * are at least 13 years old (need consent of parent or guardian if under 18). * have an hiv count of 5,000 copies/ml or more within 30 days prior to study entry. * have a cd4+ count of 50 cells/mm3 or more. exclusion criteria you will not be eligible for this study if you: * are diagnosed with hepatitis within 30 days prior to study entry. * have certain serious medical conditions, including an aids-defining clinical condition. * received chemotherapy or radiation therapy within 30 days of study entry. * have taken any nucleoside reverse transcriptase inhibitors (nrtis) for more than 2 weeks. * have ever taken 3tc. * have ever taken any non-nucleoside reverse transcriptase inhibitors (nnrtis). * have taken medications that affect your immune system within 30 days prior to study entry. * have received a vaccine within 30 days prior to study entry. * are enrolled in another anti-hiv drug study while participating in this study. * abuse alcohol or drugs. * are pregnant or breast-feeding.

Keywords: drug therapy, combination reverse transcriptase inhibitors anti-hiv agents
an open-label, multi-center, expanded treatment protocol of pasireotide lar in patients with acromegaly

Conditions: Acromegaly

Summary: the present study is planned as an expanded treatment protocol to provide acromegalic patients for whom medical therapy is appropriate access to pasireotide lar while regulatory approval for pasireotide is sought.


Eligibility criteria:
inclusion criteria: * patients with confirmed diagnosis of active acromegaly with elevated igf-1 (\>uln) and random gh (\>1 μg/l) within 30 days of screening. * patients who are not controlled by pituitary surgery or who are not eligible for or refuse surgery. * for patients on medical treatment for acromegaly the following washout periods must be completed before screening assessments are performed: * dopamine agonists (bromocriptine, cabergoline): 4 weeks * gh-receptor antagonists (pegvisomant): 8 weeks * somatostatin analogues: no washout period required * karnofsky performance status ≥ 60. exclusion criteria: * concomitant treatment with somatostatin analogues unless concomitant treatment was discontinued 28 days before first pasireotide lar injection is administrated. * concomitant treatment with growth hormone receptor (ghr)-antagonists or dopamine agonists unless concomitant treatment was discontinued and the washout period was completed before the screening assessments are performed. * patients with compression of the optic chiasm causing any visual field defect for whom surgical intervention is indicated. * patients who require a surgical intervention for relief of any sign or symptom associated with tumor compression. * patients who have undergone major surgery/surgical therapy for any cause within 4 weeks of screening. * patients who have received radiotherapy of the pituitary within 4 weeks prior to screening or have not recovered from side effects of radiotherapy. * patients who have a history of hypothyroidism and who are not adequately treated with stable doses of thyroid hormone replacement therapy. * patients with active malignant disease within the last five years (with the exception of basal cell carcinoma or carcinoma in situ of the cervix). * diabetic patients whose blood glucose is poorly controlled. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: acromegaly, pituitary diseases
healing effects of autologous platelet rich plasma on gastric ulcer caused by endoscopic submucosal dissection

Conditions: Platelet-rich Plasma; Endoscopic Submucosal Dissection

Summary: in korea, where the prevalence of gastric tumors is high, the use of esd as a treatment for gastric cancer will continue to increase. considering that there are no special measures to prevent side effects (bleeding, perforation, etc.) of this procedure, it is possible to reduce the large medical costs through the discovery of substances that can promote gastric mucosal healing. mechanism of prp-based materials in the regeneration of gastric mucosal damage can be used to understand the pathophysiology of ulcers. in the future, it can be suggested as a new treatment for gastrointestinal tract damage such as intractable ulcer, perforation, mucosal fistula, gastrointestinal bleeding caused by esophagus, small intestine and large intestine as well as ulcer treatment by endoscopic procedure.

background:in korea, where the prevalence of gastric tumors is high, the use of esd as a treatment for gastric cancer will continue to increase. considering that there are no special measures to prevent side effects (bleeding, perforation, etc.) of this procedure, it is possible to reduce the large medical costs through the discovery of substances that can promote gastric mucosal healing. platelet-rich plasma (prp) has demonstrated efficacy in preclinical endoscopic resection models. aim: evaluate the efficacy of prp on participants submitted to esd. material and methods: the investigators have evaluated a prospective clinical study. the investigators have included 10 participants submitted to esd. patients were informed and accepted to participate with a written consent. prior to endoscopy prp was obtained from autologous blood with a commercial kit. resection was performed with standard technique. immediately after the procedure, autologous prp is applied to the artificial gastric ulcer using endoscopic spray. participants were followed-up after the procedure.

Eligibility criteria:
inclusion criteria: * endoscopic lesion submitted to endoscopic resection (esd) exclusion criteria: * ineligibility to endoscopic resection * patients who declined to participate in this study * patients who had hematologic diseases
idiopathic pulmonary fibrosis registry china study

Conditions: Idiopathic Pulmonary Fibrosis

Summary: by mean of registry of newly diagnosed chinese ipf patients from more than 15 sites, this study aims to build ipf prospective cohort, set up normative clinical database and a biological specimen bank, and examine the clinical characteristics of newly diagnosed chinese ipf patients, as well as the nature history, prognosis, comorbidities and complications of ipf patients in china, the current treatment pattern, burden of illness, and quality of life of chinese ipf patients.


Eligibility criteria:
inclusion criteria: * physician diagnosed ipf during the last 3 months based upon ats/ers/jrs/alat guidelines 2011 * aged 40 years and above at recruitment * willing and able to sign an informed consent exclusion criteria: * inclusion in any interventional clinical trials * lung transplantation expected within the next 6 months.

Keywords: idiopathic pulmonary fibrosis epidemiology nature history
bioabsorbable versus durable polymer drug eluting stent (des): a meta-analysis

Conditions: Restenosis; Myocardial Infarction

Summary: evidence supporting use of bioabsorbable polymer drug eluting stents (bp-des) is uncertain. thus the investigators planned a meta-analysis to compare outcomes of bp-des versus pp-des in obstructive coronary artery disease.

evidence supporting use of bioabsorbable polymer drug eluting stents (bp-des) is uncertain. previous studies suggested that bp-des are at least as effective as durable polymer drug eluting stents (pp-des). thus the investigators planned a meta-analysis to compare outcomes of bp-des versus pp-des in obstructive coronary artery disease. medline and web databases were searched for studies comparing bp-des and pp-des for obstructive coronary disease, reporting rates of overall mortality, target lesion revascularization (tlr), myocardial infarction (mi), binary restenosis and late lumen loss (lll) with a follow-up ≥ 6 months. odds ratios (ors) will be computed from individual studies and pooled according to a fixed effect (e.g. inverse variance weighting) or random effect model in case of statistical heterogeneity. given the a priori heterogeneous nature of the observational analyses, separate subgroup analysis of studies with pla bioabsorbable polymer loaded with biolimus a19 (bp-bes) is prespecified.

Eligibility criteria:
inclusion criteria: * randomized studies * studies reporting clinical outcomes as overall death and/or acute myocardial infarction and/or late stent thrombosis (arc definition)\[\*\*\] and/or target lesion revascularization and/or late lumen loss * follow up period longer than 6 months. exclusion criteria: * duplicate reporting (in which case the manuscript reporting the largest sample or the longest follow-up was selected) * inability to compute risk estimates due to absence of clinical event in one of the groups * studies presenting composite major adverse cardiac event (mace) and not individual end points.
to evaluate the effectiveness of an injury prevention program in athletics

Conditions: Athletics; Wounds and Injuries; Prevention Program

Summary: the practice of athletics leads to risk of injuries: about 61 to 76% athletes will occurred at least one injury during a season. the prevention of athletics injuries thus represents a major challenge for all stakeholders around athletes. in team sports, injury prevention programs have been implemented and scientifically validated. however, no injury prevention programs have been implemented and scientifically validated for athletics. in this context, a primary objective will be to analyze the effectiveness of an athletics injury prevention program (aipp) to reduce the frequency (percentage) of athletes presenting at least one injury complaint related to athletic practice at long term (40 weeks). a statistician will carry out a randomized control trial in cluster (clubs with aipp and clubs without aipp), multicenter, including athletes between 15 and 40 years old and licensed in athletic clubs and followed during an athletic season.

the person in charge of the platform will collect on a weekly basis via a it-questionnaire sent out automatically every monday the following parameters: injury complaints (presence or absence, and characteristics if presence) and exposure (number of hours of athletic practice (training and competition) and intensity), and the number of aipp realization per week. the main criterion will be the frequency (percentage) of athletes presenting at least one injury complaint that have a consequence on the practice (reduction or cessation of practice).

Eligibility criteria:
inclusion criteria: * to dismissed in athletics clubs affiliated to french federation of athletics * to practice one of the disciplines of athletics * men or women aged between 15 and 40 years exclusion criteria: - patient's refusal to participate in the study and / or inability to express agreement or signing the informed consent

Keywords: program prevention injury athletics
optimal timing of endoscopic intervention in the treatment of chronic pancreatitis.

Conditions: Pancreatitis, Chronic

Summary: this study aims to determine the optimal timing of endoscopic intervention after extracorporeal shock wave lithotripsy(eswl) of chronic pancreatitis with pancreatic stones.

chronic pancreatitis（cp）is a chronic progressive fibro-inflammatory disease of the pancreas induced by a wide range of factors including genetic and environmental elements, with recurrent abdominal pain and pancreatic secretion insufficiency as its major clinical signs. chronic pancreatitis is not only a tough disease of the gastrointestinal system but also a worldwide medical problem. at present, the mess (medicine-extracorporeal shock wave lithotripsy-endoscopic retrograde cholangiopancreatography-surgery）formed by changhai hospital in cp diagnosis and treatment is gradually becoming mature, and the clinical effect of this system is obvious. however, there are still some difficulties and knowledge gaps in the clinical treatment of cp. currently, it is recommended by both domestic and foreign guidelines that ercp combined with eswl as the first-line treatment pattern for patients with chronic pancreatitis associate pain. it has previously been observed that ercp performed less than 2 days after eswl may be more likely to fail, possibly owing to eswl-induced edema. however, there is no high-quality research to demonstrate how to choose the most optimal timing of ercp after eswl for patients with indications for endoscopic treatment. this prospective, randomized controlled research has therefore aimed to determine the most optimal timing of ercp after eswl. patients with painful chronic pancreatitis and pancreatic stones larger than 5 mm in diameter will be randomly and equally assigned to two groups, which are divided according to the time interval between eswl and ercp, including the same day (\< 12 hours) subgroup and the next day ( ≥12 hours) subgroup. the cannulation success rate and stone clearance rate of the pancreatic duct will be assessed in each group to explore the most appropriate timing of ercp, and then provide an important reference basis for the clinical treatment of chronic pancreatitis.

Eligibility criteria:
inclusion criteria: 1. symptomatic adult patients diagnosed with chronic pancreatitis and main pancreatic duct positive stones（\>5mm in diameter） 2. no ercp and eswl history before the admission 3. provides informed consent exclusion criteria: 1. suspected to have malignant tumors; 2. history of pancreatic surgery or gastrojejunostomy (billroth ii); 3. with end-stage disease; 4. with contraindications to eswl or ercp, such as pregnancy, abdominal aortic aneurysm, etc. 5. acute pancreatitis within 3 days 6. pancreatic ascites

Keywords: extracorporeal shock wave lithotripsy(eswl) chronic pancreatitis endoscopic retrograde cholangiopancreatography(ercp) pancreatic stones
safety and efficacy of kalomin™ tab. in patients with acute bronchitis

Conditions: Acute Bronchitis

Summary: this is a multi-center, double-dummy, double-blind, randomized, active-controlled, parallel group phase 3 clinical trial to evaluate the efficacy and safety of kalomin™ tab. in patients with acute bronchitis. the aim of this clinical trial is to demonstrate that kalomin™ tab. is clinically non-inferior to umckamin syrup, as assessed by bss(bronchitis severity score), in the treatment of acute bronchitis after 7 days.


Eligibility criteria:
inclusion criteria: * male or female patients aged 12-75 years old * a total score of bss ≥ 5 * the duration of symptoms had to be less than 14 days and no chronic pulmonary disease * patients who voluntarily sign a written informed consent to participate in the trial exclusion criteria: * indication for antibiotic treatment(e.g. severe respiratory infection) * allergic bronchial asthma * tendency to bleed * severe heart, renal, or liver diseases or decline of immune function * chronic obstructive pulmonary disease * known or supposed hypersensitivity to investigational medication * treatment with antibiotics during the past 4 weeks prior to inclusion in the trial * women during pregnancy or lactation period * clinically significant abnormal values in the screening test(more than twice the upper limit of normal range for alt, ast, bun, and serum creatinine) * participation in any other trial within 30 days prior to inclusion in the trial * unsuitable patients for enrollment in the opinion of the investigator
a clinical study to compare the efficacy and safety of hlx10 in combination with hlx04 versus sorafenib as the first-line treatment in patients with locally advanced or metastatic hcc

Conditions: Hepatocellular Carcinoma (HCC)

Summary: this study is a randomized, double-blind, multicenter, phase iii clinical study to compare the efficacy and safety of hlx10 + hlx04 vs sorafenibas as the first-line treatment in patients with locally advanced or metastatic hcc eligible subjects in this study will be randomized to arm a or arm b at 2:1 ratio as follows: arm a (treatment group): hlx10 + hlx04 arm b (control group): sorafenib randomization is stratified by: region (asia (excluding japan) vs. others), hbv infection vs. hcv infection vs. no hbv or hcv infection, portal vein invasion or/and extrahepatic spread (with vs.without), and ecog (0 vs. 1).


Eligibility criteria:
inclusion criteria: 1. volunteer to participate in the clinical study; 2. aged ≥ 18 years and ≤ 75 years; 3. patients with histopathologically or cytologically diagnosed locally advanced or metastatic and/or unresectable hcc , or patients with clinically diagnosed hcc according to the diagnostic criteria of the american association for the study of liver diseases (aasld); 4. barcelona clinic liver cancer (bclc) stage c; or bclc stage b patients who are not candidates for radical surgery and/or locoregional therapy. 5. received no prior systemic hcc treatment (including chemotherapy, treatment with sorafenib, regorafenib, lenvatinib, or other small-molecule antiangiogenic agents); 6. at least one measurable lesion by the irrc (central radiography) as per recist v1.1 7. normal major organ functions as defined exclusion criteria: 1. patients with known hepatobiliary cell carcinoma, mixed cell carcinoma, or fibrolamellar cell carcinoma; 2. history of hepatic encephalopathy; 3. patients with portal hypertension complicated with upper gastrointestinal hemorrhage, or esophageal/gastric fundal varices with the red color sign, or high hemorrhage risk investigated by the investigator within 6 months before the randomization. subjects must receive endoscopic examinations to rule out high hemorrhage risk (e.g. red color sign and severe varices) before enrollment. 4. patients with portal vein invasion at the main portal branch (vp4), inferior vena cava involvement, or right cardiac involvement of hcc based on imaging examination. patients with portal vein invasion at the main portal branch but with unobstructed blood flow in the bilateral or unilateral branch can be enrolled; 5. central nervous system (cns) or leptomeningeal metastases; 6. positive for both hbv-dna and hcv-rna;

Keywords: locally advanced or metastatic hepatocellular carcinoma (hcc)